Cited by 39interferon and immune responsesImmune Response and InflammationImmunodeficiency and Autoimmune Disorders

Interferon Consensus Sequence Binding Protein Confers Resistance against Yersinia enterocolitica

Open access
Hein, Joachim, Kempf, Volkhard A. J., Diebold, Joachim, Bücheler, Nicole, Preger, Sonja, Horak, Ivan, Sing, Andreas, Kramer, Uwe +1 more·2000·Infection and Immunity

Abstract

Interferon consensus sequence binding protein (ICSBP)-deficient mice display enhanced susceptibility to intracellular pathogens. At least two distinct immunoregulatory defects are responsible for this phenotype. First, diminished production of reactive oxygen intermediates in macrophages results in impaired intracellular killing of microorganisms. Second, defective early interleukin-12 (IL-12) production upon microbial challenge leads to a failure in gamma interferon (IFN-γ) induction and subsequently in T helper 1 immune responses. Here, we investigated the role of ICSBP in resistance against the extracellular bacterium Yersinia enterocolitica. ICSBP−/−mice failed to produce IL-12 and IFN-γ, but also IL-4, after Yersinia challenge. In addition, granuloma formation was highly disturbed in infected ICSBP−/−mice, leading to multiple necrotic abscesses in affected organs. Consequently, ICSBP−/−mice rapidly succumbed to acute Yersinia infection. In vitro treatment of spleen cells from ICSBP−/−mice with recombinant IL-12 (rIL-12) or rIL-18 in combination with a second stimulus resulted in IFN-γ induction. In experimental therapy of infected ICSBP−/−mice, we observed that administration of rIL-12 induced IFN-γ production which was associated with improved resistance to Yersinia. In contrast, treatment with rIL-18 failed to enhance endogenous IFN-γ production but nevertheless reduced bacterial burden in ICSBP−/−mice. Although cytokine therapy with rIL-12 or rIL-18 ameliorated the course of Yersinia infection in ICSBP−/−mice, both cytokines failed to completely restore impaired immunity. Taken together, the results indicate that the transcription factor ICSBP is essential for efficient host immune defense against Yersinia. These results are important for understanding the complex host immune responses in bacterial infections.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/iai.68.3.1408-1417.2000

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Hein, J., Kempf, V. A. J., Diebold, J., Bücheler, N., Preger, S., Horak, I., Sing, A., Kramer, U., & Autenrieth, I. B.
Affiliations
  • Max-von-Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie (DE)
  • Pathologisches Institut (DE)
  • <!--label omitted: 1-->Max von Pettenkofer-Institut für Hygiene und Medizinische Mikrobiologie1 and
  • Leibniz-Forschungsinstitut für Molekulare Pharmakologie (DE)
Venue
Infection and Immunity
Published
2000-03
Volume
68
Issue
3
Pages
1408-1417
ISSN
  • 0019-9567 (ISSN-L)
  • 1098-5522
OpenAlex
W2075365138
Cited by
39
References
83
Citations by year
2025: 1 · 2024: 1 · 2023: 1 · 2020: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 4 · 2013: 2 · 2012: 1
FWCI
1.41
Type
journal article
Language
en
Open access
Locations
  • Infection and Immunity (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion)
Funders
Deutsche Forschungsgemeinschaft
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
Keywords
Yersinia enterocolitica, IL-12, IL-18, interferon-gamma, granuloma formation, cytokine therapy, T helper 1 response, IL-4
MeSH terms
Interferon Regulatory Factor-8, Animals, Interferon-gamma, Mice, Inbred C57BL, Repressor Proteins, Yersinia enterocolitica, Yersinia Infections, Mice, Knockout, Interleukin-12, Interleukin-18, Interferon Regulatory Factors, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review